The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
NCT ID: NCT06330012
Last Updated: 2024-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
50 participants
INTERVENTIONAL
2024-03-18
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer
NCT06837792
Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
NCT06928818
Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer
NCT03698383
Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy
NCT04276337
Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer
NCT00726180
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Spatial transcriptomic approch
Spatial transcriptomic approch for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
GeoMx data analysis with clinical outcome
1. List of HER2 positive breast cancer
* Stage IV disease
* Treated with T-Dxd
* Available FFPE samples
2. Prepare tissue for digital spatial proteomics
* FFPE/H\&E slide
* Region of Interest(ROI) check
* Make a Tissue microarray
* Prepare special slide for GeoMx
3. GeoMx data analysis with clinical outcome
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GeoMx data analysis with clinical outcome
1. List of HER2 positive breast cancer
* Stage IV disease
* Treated with T-Dxd
* Available FFPE samples
2. Prepare tissue for digital spatial proteomics
* FFPE/H\&E slide
* Region of Interest(ROI) check
* Make a Tissue microarray
* Prepare special slide for GeoMx
3. GeoMx data analysis with clinical outcome
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stage IV disease
* Treated with T-Dxd
* Available FFPE samples
Exclusion Criteria
* Hormone receptor positive breast cancer
* Non-available FFPE samples
* Treated except T-Dxd
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
JI-YEON, KIM
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ji-Yeon Kim
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GeoMx_Breast
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.